Dacarbazine-doxorubicin therapy ameliorated an extremely aggressive mesenteric desmoid tumor associated with familial adenomatous polyposis: Report of a case

Japanese Journal of Clinical Oncology

Volumn 38, Issue 3, 2008, Pages 222-226

  Ezumi, Koji ^a   Yamamoto, Hirofumi ^a   Takemasa, Ichiro ^a   Nomura, Masaya ^a   Ikeda, Masataka ^a   Sekimoto, Mitsugu ^a   Monden, Morito ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

Dacarbazine; Doxorubicin; Familial adenomatous polyposis; Mesenteric desmoid

Indexed keywords

DACARBAZINE; DOXORUBICIN; ETODOLAC; IMATINIB; TAMOXIFEN; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADENOMATOUS POLYP; ADULT; ARTICLE; CANCER SURGERY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DESMOID TUMOR; DISEASE ASSOCIATION; DRUG MONITORING; DRUG RESPONSE; FAMILIAL COLON POLYPOSIS; HEART DISEASE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LAPAROSCOPIC SURGERY; LEUKOPENIA; MALE; MESENTERY TUMOR; MULTIPLE CYCLE TREATMENT; PATIENT MONITORING; PROCTOCOLECTOMY; SURGICAL APPROACH; COLON POLYPOSIS; FIBROMATOSIS; MESENTERY; PERITONEUM TUMOR; REMISSION; TUMOR RECURRENCE;

ADENOMATOUS POLYPOSIS COLI; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DACARBAZINE; DOXORUBICIN; FIBROMATOSIS, AGGRESSIVE; HUMANS; MALE; MESENTERY; NEOPLASM RECURRENCE, LOCAL; PERITONEAL NEOPLASMS; PIPERAZINES; PYRIMIDINES; REMISSION INDUCTION; TAMOXIFEN;

EID: 40749155434     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyn004     Document Type: Article

References (31)

1. Gurbuz AK, Giardiello FM, Petersen GM, Krush AJ, Offerhaus GJ, Booker SV, et al. Desmoid tumors in familial adenomatous polyposis. Gut 1994;35:377-81.
2. Clark SK, Phillips RK. Desmoids in familial adenomatous polyposis. Br J Surg 1996;83:1494-504.
3. Arvanitis ML, Jagelman DG, Fazio VW, Lavery IC, McGannan E, Mortality in patients with familial adenomatous polyposis. Dis Colon Rectum 1990;33:639-42.
4. Clark SK, Neale KF, Landgrebe JC, Phillips RK. Desmoid tumours complicating familial adenomatous polyposis. Br J Surg 1999;86:1185-9.
5. Heiskanen I, Jarvinen HJ. Occurrence of desmoids tumours in familial adenomatous polyposis and results of treatment. Int J Colorectal Dis 1996;11:157-62.
6. Gega M, Yanagi H, Yoshikawa R, Noda, M, Ikeuchi H, Tsukatnoto K, et al. Successful chemotherapeutic modality of doxorubicin plus dacarbazine for the treatment of desmoids tumors in association with familial adenomatous polyposis. J Clin Oncol 2006;24:102-5.
7. Takayama T, Ohi M, Hayashi T, Miyanishi K, Nobuoka A, Nakajima T, et al. Analysis of K-ras, APC and beta-catenin in aberrant crypt foci in sporadic adenoma, cancer and familial adenomatous polyposis. Gastroenterology 2003;124:274-5.
8. Lynch HT, Fitzgibbons R, Jr. Surgery desmoid tumors and familial adenomatous polyposis: Case report and literature review. Am J Gastroenterol 1996;91:2598-601.
9. Patel SR, Benjamin RS. Desmoid tumors respond to chemotherapy: Defying the dogma in oncology. J Clin Oncol 2006;24:11-2.
10. Hausmann A, Adolph C, Vogel T, Unger A, Moeslein G. High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors. Cancer 2004;100:612-20.
11. Heinrich MC, McArthur GA, Demetri GD, Joensuu H, Bono P, Herrmann R, et al. Clinical and molecular studies of the effect of imatinib on advanced qggressive fibromatosis(desmoids tumor). J Clin Oncol 2006;24:1195-203.
12. Mace J, Sybil Biermann J, Sondak V, McGinn C, Hayes C, Thomas D, et al. Response of extraabdominal desmoid tumors to therapy with imatinib mesylate. Cancer 2002;95:2373-9.
13. Lynch HT, Fitzgibbons R, Jr, Chong S, Cavalieri J, Lynch J, Wallace F, et al. Use of doxorubicin and dacarbazine for the management of unresectable intra-abdominal desmoids in Gardner's syndrome. Dis Colon Rectum 1994;37:260-7.
14. Patel SR, Evans HL, Benjamin RS. Combination chemotherapy in adult desmoid tumors. Cancer 1993;72:3244-7.
15. Poritz LS, Blackstein M, Berk P, Gallinger S, McLeod RS, Cohen Z. Extended follow-up of patients treated with cytotoxic chemotherapy for intra-abdominal desmoids tumors. Dis Colon Rectum 2001;44:1268-73.
16. Nakada I, Ubukata H, Goto Y, Watanabe Y, Sato S, Tabuchi T, et al. Prednisolone therapy for intra-abdominal desmoids tumors in a patient with familial adenomatous polyposis. J Gastroenterol 1997; 32:255-9.
17. Bauernhofer T, Stoger H, Schmid M, Smola M, Gurtl-Lackner B, Hofler G, et al. Sequential treatment of recurrent mesenteric desmoid tumor. Cancer 1996;77:1061-5.
18. Kono T, Tomita I, Chisato N, Matsuda M, Kakisaka A, Kasai S. Successful low-dose chemotherapy using vinblastine and methotrexate for the treatment of an ileoanai pouch mesenteric desmoid tumor: Report of case. Dis Colon Rectum 2004;47:246-9.
19. Weiss AJ, Horowiz S, Lackman RD. Therapy of desmoid tumors and fibromatosis using vinorelbine. Am J Clin Oncol 1999;12:193-5.
20. Okuno SH, Edmonson JH. Combination chemotherapy for desmoid tumors. Cancer 2003;97:134-5.
21. Gottlieb JA, Benjamin RS, Baker LH, O'Bryan RM, Sinkovics JO Hoogstraten B, et al. Role of DTIC(NSC45388) in the chemotherapy of sarcoma. Cancer Treat Rep 1976;60:199-203.
22. Gottieb JA, Baker LH, Quagliana JM, Luce JK, Whitecar JP, Jr, Sinkovics JG, et al. Chemotherapy of sarcoma with a combination of adriamycin and dimethyl triazeno imidazole carboxamide. Cancer 1972;30:1632-8.
23. Legha SS, Benjamin RS, Mackay B, Ewer M, Wallace, S, Valdivieso M, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982;96:133-9.
24. Nishisho I, Nakamura Y, Miyoshi Y, Miki Y, Ando H, Horii A, et al. Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science 1991;253:665-9.
25. Nugent KP, Phillips RK, Hodqson SV, Cottrell S, Smith-Ravin J, Pack K, et al. Phenotypic expression in familial adenomatous polyposis: Partial prediction by mutation analysis. Gut 1994;35:1622-3.
26. Caspari R, Olschwang S, Friedl W, Mandl M, Boisson C, Boker T, et al. Familial adenomatous-polyposis: Desmoid tumors and lack of ophthalmic lesions (CHRPE) associated with APC mutations beyond codon 1444. Hum Mol Genet 1995;4:337-40.
27. Friedl W, Caspari R, Sengteller M, Uhlhaas S, Lamberti C, Jungck M, et al. Can APC mutation analysis contribute to therapeutic decisions in familial adenomatous polyposis? Experience from 680 FAP families. Gut 2001;48:515-21.
28. Couture J, Mitri A, Lagace R, Smits R, Berk T, Bouchard HL, et al. A germline mutation at the extreme 3′ end of the APC gene results in a severe desmoids phenotpe and is associated with overexpression of beta-catenin in the desmoids tumor. Clin Genet 2000;57:205-12.
29. Enomoto M, Konishi M, Iwama T, Utsunomiya J, Sugihara KI, Miyaki M. The relationship between frequencies of extracolonic manifestations and the position of APC germline mutation in patients with familial adenomatous polyposis. Jpn J Clin Oncol 2000;30:92-8.
30. Church JM. Desmoid tumours in patients with familial adenomatous polyposis. Semin Colon Rectal Surg 1995;6:29-32.
31. Okuno S. The enigma of desmoid tumors. Curr Treat Options Oncol 2006;7:438-43.